Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1580-1589

  Harte, Robert J A ^a   Matthews, Julian C ^a   O'Reilly, Susan M ^a   Tilsley, D W Owen ^a   Osman, Safiye ^a   Brown, Gavin ^a   Luthra, Sajinder J ^a   Brady, Frank ^a   Jones, Terry ^a   Price, Patricia M ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; FOLINIC ACID; SPARFOSIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER BLOOD FLOW; MALE; METABOLIC INHIBITION; PLASMA CLEARANCE; PRIORITY JOURNAL;

EID: 0032897391     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1580     Document Type: Article

References (54)

1. Grem JL: 5-Fluoropyrimidines, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 2). Philadelphia, PA, JB Lippincott, 1996, pp 149-212
2. Pinedo HM, Peters GF: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653-1664, 1988
3. Sotos GA, Grogan L, Allegra CJ: Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 20:11-49, 1994
4. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colon cancer: A Mid-Atlantic Oncology Program Study. J Clin Oncol 7:425-432, 1989
5. Milano G, Etienne MC, Renee N, et al: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291-1295, 1994
6. Howell JD, McArdle CS, Kerr DJ, et al: A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal metastases. Br J Cancer 76:1390-1393, 1997
7. Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88:252-258, 1996
8. Leyland-Jones B, O'Dwyer PJ: Biochemical modulation: Application of laboratory models to the clinic. Cancer Treat Rep 70:219-228, 1986
9. Allegra CJ: Biochemical modulation: A modality that has come of therapeutic age. J Clin Oncol 9:1723-1726, 1991
10. Yin MB, Zakrzewski SF, Hakala MT: Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 23:190-197, 1983
11. Peters GJ, Schornagel JH, Milano GA: Clinical pharmacokinetics of anti-metabolites, in Workman P, Graham MA (eds): Pharmacokinetics and Cancer Chemotherapy. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1993, pp 123-156
12. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330:1136-1141, 1994
13. Machover D: A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 80:1179-1187, 1997
14. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989
15. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
16. Swyryd EA, Seaver SS, Stark GR: N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture. J Biol Chem 249:6945-6950, 1974
17. Grem JL, King SA, O'Dwyer PJ, et al: Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: A review. Cancer Res 48:4441-4454, 1988
18. Martin DS, Kemeny NE: Modulation of fluorouracil by N-(phosphonacetyl)-L-aspartate: A review. Semin Oncol 19:49-55, 1992 (suppl 3)
19. Casper ES, Vale K, Williams LJ, et al: Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid. Cancer Res 43:2324-2329, 1983
20. O'Dwyer PJ, Paul AR, Walczak J, et al: Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 8:1497-1503, 1990
21. Kemeny N, Conti JA, Seiter K, et al: Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer. J Clin Oncol 10:747-752, 1992
22. Martin DS, Kemeny NE: Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials. Semin Oncol 19:228-233, 1992 (suppl 3)
23. Borden EC, Wadler S: Interferons as biochemical modulators. J Clin Oncol 14:2627-2630, 1996
24. Schwartz EL, Baptiste N, O'Connor CJ, et al: Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary results on thymidine phosphorylase. Cancer Res 54:1472-1478, 1994
25. Makower D, Wadler S, Haynes H, et al: Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo. Clin Cancer Res 3:923-929, 1997
26. Chu E, Koeller DM, Casey JL, et al: Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci U S A 88:8977-8981, 1991
27. Wadler S, Horowitz R, Mao X, et al: Effect of interferon on 5-fluorouracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaks. Cancer Chemother Pharmacol 38:529-535, 1996
28. Horowitz RW, Heerdt BG, Hu X, et al: Combination therapy with 5-fluorouracil and IFN-α2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells. Clin Cancer Res 3:1317-1322, 1997
29. Grem JL, McAtee N, Murphy RF, et al: A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 9:1811-1820, 1991
30. Yee LK, Allegra CJ, Stenberg SM, et al: Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination chemotherapy with fluorouracil, leucovorin and interferon alpha-2a. J Natl Cancer Inst 84:1820-1825, 1992
31. Grem JL, van Groeningen CJ, Ismail AA, et al: The role of interferon-alpha as a modulator of fluorouracil and leucovorin. Eur J Cancer 31A:1316-1320, 1995
32. Greco FA, Figlin R, York M, et al: Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14:2674-2681, 1996
33. DuFour R, Husseini F, Dreyfus B, et al: 5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma: A randomized study. Ann Oncol 7:575-579, 1996
34. Maxwell RJ: New techniques in the pharmacokinetic analysis of cancer drugs III: Nuclear magnetic resonance, in Workman P, Graham MA (eds): Pharmacokinetics and Cancer Chemotherapy. Cold Spring Harbor, NY, Cold Spring Harbor Press, 1993, pp 415-423
35. Tilsley DWO, Harte RJA, Jones T, et al: New techniques in the pharmacokinetic analysis of cancer drugs IV: Positron emission tomography, in Workman P, Graham MA (eds): Pharmacokinetics and Cancer Chemotherapy. Cold Spring Harbor, NY, Cold Spring Harbor Press, 1993, pp 425-442
36. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol 8:1868-1873, 1990
37. 19F nuclear magnetic resonance spectroscopy. Cancer Res 51:5806-5812, 1991
38. Presant CA, Wolf W, Waluch V, et al: Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 343:1184-1187, 1994
39. Dimitrakopoulou A, Strauss LG, Clonus JH, et al: Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 34:1075-1081, 1993
40. 18F]fluorouracil tissue concentration measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 57:3415-3423, 1997
41. Woods RP, Cherry SR, Mazziotta JC: Rapid automated algorithm for alignment and reslicing PET images. J Comput Assist Tomogr 16:620-633, 1992
42. Lammertsma AA, Wilson CB, Taylor CJV, et al: Measurement of blood flow and exchangeable volume of distribution of water in breast tumors using dynamic positron emission tomography. J Nucl Med 31:746-747, 1990
43. Wilson CBJH, Lammertsma AA, McKenzie CG, et al: Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and noninvasive dynamic method. Cancer Res 52:1592-1597, 1992
44. Wilson CW: The study of blood flow and anticancer agents in human tumours using positron emission tomography (doctoral thesis). London, United Kingdom, University of London, 1992
45. Harte RJA: Pharmacokinetic evaluation of anticancer drugs using positron emitting nuclides (doctoral thesis). Bristol, United Kingdom, University of Bristol, 1996
46. 18F]fluorouracil using HPLC and a study of its metabolic profile in rats. J Labelled Compd Radiopharm 32:521-522, 1993
47. Robb RA: A software system for interactive and quantitative analysis of biomedical images, in Hohne KH, Fuchs H, Pizer SM (eds): 3D Imaging in Medicine: Algorithms, Systems, Applications. New York, NY, Springer-Verlag, 1990, 333-361
48. Ranicar ASO, Williams CW, Schnorr L, et al: The on-line monitoring of continuously withdrawn arterial blood during PET studies using a BGO/photomultiplier assembly and non-stick tubing. Med Prog Technol 17:259-264, 1991
49. Altman DG: Practical Statistics for Medical Research. London, United Kingdom, Chapman and Hall, 1991
50. Collins JM, Dedrick RL, King FG, et al: Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routes. Clin Pharmacol Ther 28:235-246, 1980
51. Heggie GD, Sommadossi JP, Cross DS, et al: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 47:2203-2206, 1987
52. van Groeningen CJ, Pinedo HM, Heddes J, et al: Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48:6956-6961, 1988
53. Fleming RA, Milano G, Thyss A, et al: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902, 1992
54. Baker SD, Khor SP, Adjei AA, et al: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14:3085-3096, 1996